子宫颈癌的免疫疗法
Immunotherapy for Uterine Cervical Cancer.
作者信息
Kagabu Masahiro, Nagasawa Takayuki, Fukagawa Daisuke, Tomabechi Hidetoshi, Sato Saiya, Shoji Tadahiro, Baba Tsukasa
机构信息
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Iwate 020-8505, Japan.
出版信息
Healthcare (Basel). 2019 Sep 17;7(3):108. doi: 10.3390/healthcare7030108.
Cervical cancer is a malignant neoplastic disease that is the fourth most commonly occurring cancer in women worldwide. Since the introduction of angiogenesis inhibitors, treatments for recurrent and advanced cervical cancers have improved significantly in the past five years. However, the median overall survival in advanced cervical cancer is 16.8 months, with a 5-year overall survival rate of 68% for all stages, indicating that the effects of the treatment are still unsatisfactory. The development of a new treatment method is therefore imperative. Recently, in the clinical oncology field, remarkable progress has been made in immunotherapy. Immunotherapy is already established as standard therapy in some fields and in some types of cancers, and its clinical role in all areas, including the gynecology field, will change further based on the outcomes of currently ongoing clinical trials. This manuscript summarizes the results from previous clinical trials in cervical cancer and describes the ongoing clinical trials, as well as future directions.
宫颈癌是一种恶性肿瘤疾病，是全球女性中第四大常见癌症。自从引入血管生成抑制剂以来，复发性和晚期宫颈癌的治疗在过去五年中有了显著改善。然而，晚期宫颈癌的中位总生存期为16.8个月，所有阶段的5年总生存率为68%，这表明治疗效果仍不尽人意。因此，开发新的治疗方法势在必行。最近，在临床肿瘤学领域，免疫疗法取得了显著进展。免疫疗法在某些领域和某些类型的癌症中已成为标准疗法，并且基于目前正在进行的临床试验结果，其在包括妇科领域在内的所有领域的临床作用将进一步改变。本手稿总结了先前宫颈癌临床试验的结果，并描述了正在进行的临床试验以及未来的方向。
Zotero 插件